Prema Nedungadi1,2, Akshay Iyer1, Georg Gutjahr1, Jasmine Bhaskar1,2, Asha B Pillai3. 1. Center for Research in Analytics & Technology in Education, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, India. 2. Department of Computer Science, School of Engineering, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, India. 3. Division of Pediatric Hematology/Oncology, Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract
PURPOSE OF REVIEW: This article discusses the advances, methods, challenges, and future directions of data-driven methods in advancing precision oncology for biomedical research, drug discovery, clinical research, and practice. RECENT FINDINGS: Precision oncology provides individually tailored cancer treatment by considering an individual's genetic makeup, clinical, environmental, social, and lifestyle information. Challenges include voluminous, heterogeneous, and disparate data generated by different technologies with multiple modalities such as Omics, electronic health records, clinical registries and repositories, medical imaging, demographics, wearables, and sensors. Statistical and machine learning methods have been continuously adapting to the ever-increasing size and complexity of data. Precision Oncology supportive analytics have improved turnaround time in biomarker discovery and time-to-application of new and repurposed drugs. Precision oncology additionally seeks to identify target patient populations based on genomic alterations that are sensitive or resistant to conventional or experimental treatments. Predictive models have been developed for cancer progression and survivorship, drug sensitivity and resistance, and identification of the most suitable combination treatments for individual patient scenarios. In the future, clinical decision support systems need to be revamped to better incorporate knowledge from precision oncology, thus enabling clinical practitioners to provide precision cancer care. SUMMARY: Open Omics datasets, machine learning algorithms, and predictive models have enabled the advancement of precision oncology. Clinical decision support systems with integrated electronic health record and Omics data are needed to provide data-driven recommendations to assist clinicians in disease prevention, early identification, and individualized treatment. Additionally, as cancer is a constantly evolving disorder, clinical decision systems will need to be continually updated based on more recent knowledge and datasets.
PURPOSE OF REVIEW: This article discusses the advances, methods, challenges, and future directions of data-driven methods in advancing precision oncology for biomedical research, drug discovery, clinical research, and practice. RECENT FINDINGS: Precision oncology provides individually tailored cancer treatment by considering an individual's genetic makeup, clinical, environmental, social, and lifestyle information. Challenges include voluminous, heterogeneous, and disparate data generated by different technologies with multiple modalities such as Omics, electronic health records, clinical registries and repositories, medical imaging, demographics, wearables, and sensors. Statistical and machine learning methods have been continuously adapting to the ever-increasing size and complexity of data. Precision Oncology supportive analytics have improved turnaround time in biomarker discovery and time-to-application of new and repurposed drugs. Precision oncology additionally seeks to identify target patient populations based on genomic alterations that are sensitive or resistant to conventional or experimental treatments. Predictive models have been developed for cancer progression and survivorship, drug sensitivity and resistance, and identification of the most suitable combination treatments for individual patient scenarios. In the future, clinical decision support systems need to be revamped to better incorporate knowledge from precision oncology, thus enabling clinical practitioners to provide precision cancer care. SUMMARY: Open Omics datasets, machine learning algorithms, and predictive models have enabled the advancement of precision oncology. Clinical decision support systems with integrated electronic health record and Omics data are needed to provide data-driven recommendations to assist clinicians in disease prevention, early identification, and individualized treatment. Additionally, as cancer is a constantly evolving disorder, clinical decision systems will need to be continually updated based on more recent knowledge and datasets.
Entities:
Keywords:
Artificial intelligence; Big data in health; Clinical decision support; Health analytics; Omics; Personalized medicine; Precision medicine; Precision oncology; Predictive analytics
Authors: Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes Journal: Nature Date: 2012-03-28 Impact factor: 49.962
Authors: Shaun Treweek; Doug G Altman; Peter Bower; Marion Campbell; Iain Chalmers; Seonaidh Cotton; Peter Craig; David Crosby; Peter Davidson; Declan Devane; Lelia Duley; Janet Dunn; Diana Elbourne; Barbara Farrell; Carrol Gamble; Katie Gillies; Kerry Hood; Trudie Lang; Roberta Littleford; Kirsty Loudon; Alison McDonald; Gladys McPherson; Annmarie Nelson; John Norrie; Craig Ramsay; Peter Sandercock; Daniel R Shanahan; William Summerskill; Matt Sydes; Paula Williamson; Mike Clarke Journal: Trials Date: 2015-06-05 Impact factor: 2.279